Cancer News
Immunotherapy: Extending Its Reach, Predicting Responses

High Price Tag for Cologuard Confirmed, but Test Is Welcomed

Stark Differences in Cancer Survival Across the Globe

What's Hot at 2014 San Antonio Breast Cancer Symposium?

Obesity Linked to Half a Million Cancer Cases Worldwide
Immunotherapy breakthrough for advanced bladder cancer

Saatchi Bill threatens to undermine Hippocratic Oath

More public health interventions required to tackle grim reaper of 'lifestyle' diseases

Survival differences seen for advanced-stage laryngeal cancer

How environment contributes to several human diseases
Obesity Tied to Half a Million Cancers Worldwide, Report Shows

EPA Issues Tougher Rules on Ozone Emissions

New Device May Make Mammograms More Comfortable

Rx for Better Health Care: Kindness and Compassion

FDA Adds 'Boxed Warning' to Devices Used to Remove Uterine Fibroids
UCLA Scientists Discover Why Patients Respond to a Life-Saving Melanoma Drug

UCLA Researchers Unlock Protein Key to Harnessing Regenerative Power of Blood Stem Cells to Fight Cancer

UCLA Researchers Identify Unique Protein Key to the Development of Blood Stem Cells

UCLA Study Finds Ancient Chinese Exercise Lessens Inflammation in Breast Cancer Survivors

New Discovery by UCLA Researchers Could Lead to More Targeted Head and Neck Cancer Therapies
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: A pooled analysis of individual patient data from four randomised controlled trials

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: A multicentre, open-label, phase 2 trial

First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor–positive breast cancer: A trial of the Eastern Cooperative Oncology Group

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: A randomized phase II study